Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
- S-4 Registration of securities issued in business combination transactions
- 10.10 Celularity Inc. [2017 Equity Incentive Plan]
- 10.11 Form of Celularity Stock Option Grant Notice, Option Agreement and Notice of Exercise Under the 2017 Equity Incentive Plan
- 10.14 Celularity Inc. Annual Incentive Plan
- 10.15 Employment Agreement by and Between Celularity and Robert J. Hariri, Dated As of January 7, 2021
- 10.16 Employment Agreement by and Between Celularity and David C. Beers, Dated As of January 7, 2021
- 10.17 Employment Agreement by and Between Celularity and Gregory Berk, Dated As of January 7, 2021
- 10.18 Employment Agreement by and Between Celularity and Stephen A. Brigido, Dated As of January 7, 2021
- 10.19 Employment Agreement by and Between Celularity and Keary Dunn, Dated As of January 7, 2021
- 10.20 Employment Agreement by and Between Celularity and John R. Haines, Dated As of January 7, 2021
- 10.21 Employment Agreement by and Between Celularity and Xiaokui Zhang, Dated As of January 7, 2021
- 10.27 Warrant to Purchase Series B Preferred Stock of Celularity Inc., by and Between Celularity Inc. and Dragasac Limited, Dated January 9, 2020
- 10.28 Form of Warrant to Purchase Series B Preferred Stock of Celularity Inc., Dated March 16, 2020
- 10.29 Form of Amendment NO.1 to Warrant to Purchase Series B Preferred Stock of Celularity Inc., Dated As of January 8, 2021 by and Between Celularity Inc. and [the Starr Group] C.V. Starr & Co., Inc.
- 10.30 Amendment NO.1 to Warrant to Purchase Series B Preferred Stock of Celularity Inc., Dated As of March 16, 2020 by and Between Celularity Inc. and Dragasac Limited
- 10.31 Amendment NO.2 to Warrant to Purchase Series B Preferred Stock of Celularity Inc., Dated As of January 8, 2021 by and Between Celularity Inc. and Dragasac Limited
- 10.32 Lease Agreement, Dated March 13, 2019, by and Between LSREF4 Turtle, LLC and Celularity Inc.
- 23.1 Consent of Independent Registered Public Accounting Firm of GX Acquisition Corp
- 23.2 Consent of Independent Registered Public Accounting Firm of Celularity Inc
- 99.2 Consent of Robert J. Hariri to Be Named As a Director
- 99.3 Consent of John Sculley to Be Named As a Director
- 99.4 Consent of Peter Diamandis to Be Named As a Director
- 99.5 Consent of Lim Kok Thay to Be Named As a Director
- 99.6 Consent of Robin L. Smith to Be Named As a Director
- 99.7 Consent of Andrew C. Von Eschenbach to Be Named As a Director
Associated filings
- 28 Jun 21 EFFECT Notice of effectiveness
- 25 Jun 21 424B3 Prospectus supplement
- 22 Jun 21 S-4/A Registration of securities issued in business combination transactions (amended)
- 7 Jun 21 S-4/A Registration of securities issued in business combination transactions (amended)
- 23 Apr 21 S-4/A Registration of securities issued in business combination transactions (amended)
- 29 Mar 21 S-4/A Registration of securities issued in business combination transactions (amended)
-
25 Jan 21 S-4 Registration of securities issued in business combination transactions
CELU similar filings
- 7 Jun 21 Registration of securities issued in business combination transactions (amended)
- 23 Apr 21 Registration of securities issued in business combination transactions (amended)
- 29 Mar 21 Registration of securities issued in business combination transactions (amended)
- 25 Jan 21 Registration of securities issued in business combination transactions
Filing view
External links
Exhibit 99.7
January 17, 2021
GX Acquisition Corp.
1325 Avenue of the Americas, 25th Floor
New York, NY 10019
Consent to Reference in Proxy Statement/Prospectus
GX Acquisition Corp. (the “Company”) is filing a Registration Statement on Form S-4 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”). In connection therewith, I hereby consent, pursuant to Rule 438 of the Securities Act, to the reference to me in the proxy statement/prospectus included in such Registration Statement as a future member of the board of directors of the Company, such appointment to commence upon the effective time of the merger described in the proxy statement/prospectus.
Sincerely, | ||
/s/ Andrew von Eschenbach | ||
Name: | Andrew von Eschenbach, MD |